KB-1165

AZD8205-hIgG1

Background

AZD8205 is an ADC, administered by IV infusion, that consists of a human anti-B7-H4 antibody conjugated via a cleavable linker to a topoisomerase I inhibitor (TOP1i) warhead. B7-H4 is a transmembrane protein that binds to an unknown receptor on activated T cells, inhibiting their function. It is highly expressed by a wide variety of tumors including cholangiocarcinoma (CCA) and breast, ovarian and endometrial cancers, and is associated with poor prognosis. AZD8205 specifically binds to B7-H4 expressing tumor cells and is internalized. The TOP1i warhead is released, interfering with TOP1 during DNA replication leading to transcription-mediated DNA damage and cell death.

Specifications

Catalog Number:
KB-1165
Cell Line Name:
AZD8205-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
B7H4
Species Reactivity:
Human
Application:
ELISA | FACS | KD
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA | FACS | KD

References

1.Meric-Bernstam, Funda, Oh, Do-Youn, Naito, Yoichi, Shimizu, Toshio, Chung, Vincent, Park, Haeseong, Gaillard, Stephanie, First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors. Journal of Clinical Oncology
Please enable JavaScript in your browser to complete this form.